5 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Opevesostat: new trials by email Literature Review of Opevesostat trials Research Report on Opevesostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) Opevesostat, Prednisone, Fludrocortisone acetate - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2026-05-11 | 2026-06-25 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) Opevesostat, Prednisone, Fludrocortisone acetate - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2025-05-13 | 2026-02-24 |
| A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012) Opevesostat, Prednisone, Fludrocortisone acetate - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-12-18 | 2025-05-25 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-01-30 | 2026-03-19 |
| A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 7 | 2023-11-14 | 2026-04-27 |
Prostatic Neoplasms (2) · Prostatic Neoplasms, Castration-Resistant (2) · Neoplasm Metastasis (1)
United States (5) · Australia (2) · Canada (2) · Chile (2) · France (2) · Germany (2) · Ireland (2) · Israel (2) · Italy (2) · Japan (2) · New Zealand (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2)
2023 (1)